Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert A Hauser

Showing results (61-70 of 266) with videos related to

Pageof 27
Sort By:
Postgraduate Medicine|June 4, 2021
On demand therapy for Parkinson's disease patients: Opportunities and choicesRobert A Hauser, Peter A LeWitt, Cynthia L Comella
Parkinson'S Disease|July 4, 2012
A(2A) Receptor Antagonism and Dyskinesia in Parkinson's DiseaseMicaela Morelli, Fabio Blandini, Nicola Simola, et al.
Journal of Parkinson'S Disease|June 23, 2020
Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome DyskinesiaRobert A Hauser, Leonid Zeitlin, Stanley Fisher, et al.
Expert Review of Neurotherapeutics|January 28, 2021
Istradefylline - a first generation adenosine A<sub>2A</sub> antagonist for the treatment of Parkinson's diseasePeter Jenner, Akihisa Mori, Stephen D Aradi, et al.
Movement Disorders Clinical Practice|January 15, 2019
Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson DiseaseRobert A Hauser, Italo Biaggioni, L Arthur Hewitt, et al.
Clinical Parkinsonism & Related Disorders|August 13, 2025
How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson's diseaseRobert A Hauser, Yasar Torres-Yaghi, Stanley Fisher, et al.
The International Journal of Neuroscience|March 19, 2016
Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studiesRobert A Hauser, Victor Abler, Eli Eyal, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 7, 2006
Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's diseaseRobert A Hauser, Laurence Salin, Nolwenn Juhel, et al.
NPJ Parkinson'S Disease|March 19, 2022
Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson's diseaseRobert A Hauser, Judy Lytle, Andrea E Formella, et al.
Current Treatment Options in Neurology|March 12, 2003
Autonomic Nervous System Dysfunction in Parkinson's DiseaseTheresa A. Zesiewicz, Matthew J. Baker, Mervat Wahba, et al.
Pageof 27

Showing results (61-70 of 266) with videos related to

Sort By:
Pageof 27
Postgraduate Medicine|June 4, 2021
On demand therapy for Parkinson's disease patients: Opportunities and choicesRobert A Hauser, Peter A LeWitt, Cynthia L Comella
Parkinson'S Disease|July 4, 2012
A(2A) Receptor Antagonism and Dyskinesia in Parkinson's DiseaseMicaela Morelli, Fabio Blandini, Nicola Simola, et al.
Journal of Parkinson'S Disease|June 23, 2020
Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome DyskinesiaRobert A Hauser, Leonid Zeitlin, Stanley Fisher, et al.
Expert Review of Neurotherapeutics|January 28, 2021
Istradefylline - a first generation adenosine A<sub>2A</sub> antagonist for the treatment of Parkinson's diseasePeter Jenner, Akihisa Mori, Stephen D Aradi, et al.
Movement Disorders Clinical Practice|January 15, 2019
Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson DiseaseRobert A Hauser, Italo Biaggioni, L Arthur Hewitt, et al.
Clinical Parkinsonism & Related Disorders|August 13, 2025
How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson's diseaseRobert A Hauser, Yasar Torres-Yaghi, Stanley Fisher, et al.
The International Journal of Neuroscience|March 19, 2016
Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studiesRobert A Hauser, Victor Abler, Eli Eyal, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 7, 2006
Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's diseaseRobert A Hauser, Laurence Salin, Nolwenn Juhel, et al.
NPJ Parkinson'S Disease|March 19, 2022
Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson's diseaseRobert A Hauser, Judy Lytle, Andrea E Formella, et al.
Current Treatment Options in Neurology|March 12, 2003
Autonomic Nervous System Dysfunction in Parkinson's DiseaseTheresa A. Zesiewicz, Matthew J. Baker, Mervat Wahba, et al.
Pageof 27